pituitrin and Hypoplastic-Left-Heart-Syndrome

pituitrin has been researched along with Hypoplastic-Left-Heart-Syndrome* in 2 studies

Reviews

1 review(s) available for pituitrin and Hypoplastic-Left-Heart-Syndrome

ArticleYear
Practical use of alpha blockade strategy in the management of hypoplastic left heart syndrome following stage one palliation with a Blalock-Taussig shunt.
    Seminars in thoracic and cardiovascular surgery. Pediatric cardiac surgery annual, 2004, Volume: 7

    Alpha blockade with phenoxybenzamine has been used in the postoperative management after the Norwood operation. The principle of this approach is the increase in systemic cardiac output by maximal dilation of the systemic circulation. This effect results in a more stable parallel circulation through prevention of fluctuations in systemic vascular resistance in the early postoperative period. We have incorporated this approach in our postoperative management protocol and have observed a decrease in sudden cardiac collapse. This article describes the practical use of alpha blockade strategy, its clinical application, and the most common clinical scenarios observed during the initial hours following stage one palliation with a Blalock-Taussig shunt for hypoplastic left heart syndrome in our cardiac surgery unit.

    Topics: Adrenergic alpha-Antagonists; Algorithms; Cardiac Output; Cardiac Surgical Procedures; Humans; Hypoplastic Left Heart Syndrome; Infant, Newborn; Palliative Care; Phenoxybenzamine; Treatment Outcome; Vasoconstrictor Agents; Vasopressins

2004

Other Studies

1 other study(ies) available for pituitrin and Hypoplastic-Left-Heart-Syndrome

ArticleYear
Vasopressin reversal of phenoxybenzamine-induced hypotension after the Norwood procedure.
    The Journal of thoracic and cardiovascular surgery, 2002, Volume: 123, Issue:5

    Topics: Cardiac Surgical Procedures; Follow-Up Studies; Heart Function Tests; Hemodynamics; Humans; Hypoplastic Left Heart Syndrome; Hypotension; Infant, Newborn; Male; Phenoxybenzamine; Postoperative Period; Risk Assessment; Treatment Outcome; Vasopressins

2002